Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses NRIX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NRIX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Arthur Sands | $674,584 | $0 | $0 | $5,166,196 | $510,000 | $0 | $23,358 | $6,374,138 |
| President, Chief Executive Officer and Director | ||||||||
| Gwenn Hansen | 556,000 | 0 | 770,816 | 861,033 | 307,440 | 0 | 2,835 | 2,498,124 |
| Chief Scientific Officer | ||||||||
| Hans van Houte | 545,833 | 0 | 587,216 | 861,033 | 298,238 | 0 | 4,183 | 2,296,503 |
| Chief Financial Officer | ||||||||
| Christine Ring | 527,500 | 0 | 587,216 | 861,033 | 283,815 | 0 | 3,773 | 2,263,337 |
| Chief Legal Officer and Chief Compliance Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Arthur Sands | $6,374,138 | $5,812,862 | $4,363,120 | +561,276 |
| Gwenn Hansen | 2,498,124 | 2,033,860 | 1,632,757 | +464,264 |
| Hans van Houte | 2,296,503 | 2,016,482 | 1,611,987 | +280,021 |
| Christine Ring | 2,263,337 | 2,016,484 | — | +246,853 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Christine Ring | Chief Legal Officer | 2026-04-02 | D | 8,148 | $15 | $124,149 | Common, open-market sale | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-04-30 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-04-30 | A | 3,750 | 0 | 0 | Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-04-30 | D | 2,388 | 17 | 39,749 | Common, open-market sale | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-04-30 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-04-30 | D | 2,858 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-04-30 | D | 3,214 | 17 | 53,498 | Common, open-market sale | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-04-30 | D | 2,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-04-30 | D | 2,858 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-04-30 | A | 2,858 | 0 | 0 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-04-30 | A | 3,750 | 0 | 0 | Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-04-30 | D | 3,214 | 17 | 53,498 | Common, open-market sale | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-04-30 | A | 2,858 | 0 | 0 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-04-30 | A | 2,858 | 0 | 0 | Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-04-30 | D | 2,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-04-30 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-04-30 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-04-30 | A | 3,750 | 0 | 0 | Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-04-30 | D | 2,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-04-30 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-04-30 | D | 2,858 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-04-30 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-05-01 | D | 5,394 | 17 | 90,407 | Common, open-market sale | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-05-04 | D | 8,148 | 17 | 138,210 | Common, open-market sale | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-05-05 | D | 582 | 17 | 9,996 | Common, open-market sale | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-05-05 | D | 13,473 | 17 | 223,323 | Common, open-market sale | Form 4 ↗ |
| Julia P. Gregory | Director | 2026-05-15 | A | 31,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roy D. Baynes | Director | 2026-05-15 | A | 31,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul M. Silva | Director | 2026-05-15 | A | 31,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward C. Saltzman | Director | 2026-05-15 | A | 31,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Anil Kapur | Director | 2026-05-15 | A | 31,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Judith A. Reinsdorf | Director | 2026-05-15 | A | 31,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David L. Lacey | Director | 2026-05-15 | A | 31,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Roger Dansey | Director | 2026-05-15 | A | 31,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-06-02 | D | 3,422 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-06-02 | D | 8,148 | 17 | 135,253 | Common, open-market sale | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-06-02 | A | 3,422 | 2 | 6,365 | Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-06-25 | D | 5,394 | 20 | 107,880 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-06-25 | D | 28,935 | 20 | 580,506 | Common, open-market sale | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-06-25 | D | 15,602 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-06-25 | A | 15,602 | 9 | 136,049 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-06-25 | A | 13,333 | 7 | 96,798 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-06-25 | D | 13,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-02 | A | 5,787 | 9 | 50,463 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-02 | D | 5,221 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-02 | D | 11,008 | 24 | 259,366 | Common, open-market sale | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-02 | A | 5,221 | 2 | 9,711 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-02 | D | 5,787 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-07-30 | A | 3,572 | 0 | 0 | Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-07-30 | A | 3,750 | 0 | 0 | Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-07-30 | D | 2,858 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-07-30 | D | 3,572 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-30 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-30 | D | 3,847 | 23 | 89,954 | Common, open-market sale | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-07-30 | D | 3,847 | 23 | 89,954 | Common, open-market sale | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-07-30 | A | 3,572 | 0 | 0 | Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-07-30 | D | 2,858 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-07-30 | D | 3,572 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-30 | D | 2,858 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-30 | D | 3,572 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-30 | A | 3,572 | 0 | 0 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-30 | A | 2,858 | 0 | 0 | Common | Form 4 ↗ |
| Christine Ring | Chief Legal Officer | 2026-07-30 | A | 3,750 | 0 | 0 | Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-07-30 | A | 2,858 | 0 | 0 | Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-07-30 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-07-30 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-07-30 | D | 2,845 | 23 | 66,524 | Common, open-market sale | Form 4 ↗ |
| Hans van Houte | Chief Financial Officer | 2026-07-30 | A | 2,858 | 0 | 0 | Common | Form 4 ↗ |
| Gwenn Hansen | Chief Scientific Officer | 2026-07-30 | A | 3,750 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Gwenn Hansen | OPTION | 2025-02-11 | — | — | 75,000 | — | $861,033 |
| Gwenn Hansen | RSU | 2025-02-11 | — | — | 34,300 | — | 587,216 |
| Arthur Sands | OPTION | 2025-02-11 | — | — | 450,000 | — | 5,166,196 |
| Gwenn Hansen | RSU | 2025-10-14 | — | — | 20,000 | — | 183,600 |
| Christine Ring | RSU | 2025-02-11 | — | — | 34,300 | — | 587,216 |
| Christine Ring | OPTION | 2025-02-11 | — | — | 75,000 | — | 861,033 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Gwenn Hansen | $770,816 | $0 | $861,033 | 0.0% |
| Arthur Sands | 0 | 0 | 5,166,196 | 0.0% |
| Christine Ring | 587,216 | 0 | 861,033 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Arthur Sands | Option | 337,500 | 17.12 | — |
| Arthur Sands | Option | 37,334 | 10.83 | — |
| Hans van Houte | RSU | 28,584 | — | 505,365 |
| Gwenn Hansen | RSU | 4,000 | — | 70,720 |
| Christine Ring | RSU | 28,584 | — | 505,365 |
| Christine Ring | Option | 56,250 | 17.12 | — |
| Gwenn Hansen | RSU | 28,584 | — | 505,365 |
| Christine Ring | Option | 62,500 | 8.72 | — |
| Hans van Houte | Option | 56,250 | 17.12 | — |
| Hans van Houte | Option | 22,500 | 18.5 | — |
| Gwenn Hansen | RSU | 22,500 | — | 397,800 |
| Gwenn Hansen | Option | 7,409 | 10.83 | — |
| Gwenn Hansen | RSU | 3,207 | — | 56,700 |
| Gwenn Hansen | Option | 4,810 | 19.49 | — |
| Gwenn Hansen | RSU | 20,000 | — | 353,600 |
| Arthur Sands | Option | 75,000 | 18.5 | — |
| Arthur Sands | Option | 333,334 | 8.72 | — |
| Christine Ring | RSU | 4,000 | — | 70,720 |
| Arthur Sands | Option | 12,500 | 18.89 | — |
| Hans van Houte | RSU | 2,887 | — | 51,042 |
| Hans van Houte | RSU | 4,000 | — | 70,720 |
| Christine Ring | RSU | 1,925 | — | 34,034 |
| Hans van Houte | RSU | 22,500 | — | 397,800 |
| Gwenn Hansen | Option | 56,250 | 17.12 | — |
| Hans van Houte | Option | 7,409 | 10.83 | — |
| Christine Ring | Option | 7,409 | 10.83 | — |
| Hans van Houte | Option | 4,329 | 19.49 | — |
| Hans van Houte | Option | 62,500 | 8.72 | — |
| Gwenn Hansen | Option | 62,500 | 8.72 | — |
| Christine Ring | RSU | 22,500 | — | 397,800 |
| Christine Ring | Option | 7,537 | 18.5 | — |
| Gwenn Hansen | Option | 11,306 | 18.5 | — |
| Christine Ring | Option | 2,886 | 19.49 | — |
An appropriate, well-designed compensation program should align executive interests with the drivers of growth and stockholder returns by supporting the achievement of our primary business goals. Further, our compensation program must enable us to attract and retain employees whose talents, expertise and leadership can drive our success and sustained growth in long-term stockholder value.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc (Human Capital Solutions practice) |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-15 | 72,458,920 | 6,895,394 | 573,204 | 91.31% | Passed |
| 2025 | 2025-05-19 | 49,788,975 | 11,341,365 | 92,540 | 81.45% | Passed |
| 2024 | 2024-05-20 | 30,364,001 | 4,022,082 | 77,428 | 88.3% | Passed |
| 2023 | 2023-05-04 | 19,907,448 | 12,499,830 | 1,644,715 | 61.43% | Passed |
| 2022 | 2022-05-05 | 34,032,385 | 1,380,760 | 6,878 | 96.1% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-15 | 91.31%a |
| 2025 | 2025-05-19 | 81.45%b |
| 2024 | 2024-05-20 | 88.3%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Broker Non-Votes Abstentions occur when shares present at the Annual Meeting are marked "Abstain." Under Delaware law, abstentions are counted as present and entitled to vote for purposes of determining whether a quorum is present but are voted neither "for" or "against" a matter, and therefore, at the Annual Meeting, abstentions will have no effect on Proposals 1, 2 or 3.”.
c. Approved under the standard stated in the filing — “Broker Non-Votes Abstentions occur when shares present at the Annual Meeting are marked "Abstain." Under Delaware law, abstentions are counted as present and entitled to vote for purposes of determining whether a quorum is present but are voted neither "for" or "against" a matter, and therefore, at the Annual Meeting, abstentions will have no effect on Proposals 1, 2 or 3.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 23 : 1 |
|---|---|
| CEO total compensation | $6,374,138 |
| Median employee compensation | $274,252 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Roy D. BaynesIndependent · Clinical and Commercialization (Chair) · Newly elected | $44,479 | $0 | $624,307 | — | $0 | $668,786 |
| Roger DanseyIndependent · Clinical and Commercialization · Newly elected | 4,792 | 0 | 416,892 | — | 0 | 421,684 |
| Julia P. GregoryIndependent · Board Chair · Audit · Nominating/Governance | 101,458 | 0 | 157,509 | — | 1 | 258,968 |
| Paul M. SilvaIndependent · Audit (Chair) · Compensation | 72,813 | 0 | 157,509 | — | 0 | 230,322 |
| Judith A. ReinsdorfIndependent · Audit · Nominating/Governance (Chair) | 71,563 | 0 | 157,509 | — | 0 | 229,072 |
| David L. LaceyIndependent · Compensation (Chair) · Clinical and Commercialization | 69,063 | 0 | 157,509 | — | -1 | 226,571 |
| Edward C. SaltzmanIndependent · Compensation · Clinical and Commercialization | 62,708 | 0 | 157,509 | — | 1 | 220,218 |
| Anil KapurIndependent · Nominating/Governance · Clinical and Commercialization | 60,417 | 0 | 157,509 | — | 0 | 217,926 |
| Lori A. KunkelIndependent · Departed during FY | 50,938 | 0 | 157,509 | — | 0 | 208,447 |
| Arthur T. SandsEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $157,509 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 20,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $538,231 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $1 |
| Total cost of the board | $538,232 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Nurix Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Nurix Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | RAPT Therapeutics, Inc. | 2024 | Brian Wong | $630,000 | $0 | $5,927,297 | $416,000 | $6,979,539 |
| 2 | Nurix Therapeutics | 2025 | Arthur Sands | 674,584 | 0 | 5,166,196 | 510,000 | 6,374,138 |
| 3 | Celldex Therapeutics, Inc. | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 4 | Mersana Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| — | Gritstone bio, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Kezar Life Sciences, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Nurix Therapeutics | 125% | Options 100 | not disclosed | Aon plc (Human Capital Solutions practice) |
| Celldex Therapeutics, Inc. | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Gritstone bio, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Kezar Life Sciences, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Mersana Therapeutics, Inc. | 85% | Options 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| RAPT Therapeutics, Inc. | 120% | Options 100 | not disclosed | Aon plc/Radford |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Arthur Sands | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Summary Compensation Table”. As printed: 6,374,138. Filing ↗machine: r2 · c21 · span 570227–570236 |
| 2 | Section 01, Gwenn Hansen | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Summary Compensation Table”. As printed: 2,498,124. Filing ↗machine: r8 · c21 · span 593328–593337 |
| 3 | Section 01, Hans van Houte | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Summary Compensation Table”. As printed: 2,296,503. Filing ↗machine: t131 · r5 · c21 · span 581960–581969 |
| 4 | Section 01, Christine Ring | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Summary Compensation Table”. As printed: 2,263,337. Filing ↗machine: r11 · c21 · span 605140–605149 |
| 5 | Section 03, Gwenn Hansen OPTION | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r9 · c30 · span 673933–673940 |
| 6 | Section 03, Gwenn Hansen RSU | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r10 · c30 · span 678667–678674 |
| 7 | Section 03, Arthur Sands OPTION | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r4 · c30 · span 647446–647455 |
| 8 | Section 03, Gwenn Hansen RSU | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r11 · c30 · span 684196–684203 |
| 9 | Section 03, Christine Ring RSU | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r14 · c30 · span 699098–699105 |
| 10 | Section 03, Christine Ring OPTION | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t143 · r13 · c30 · span 694628–694635 |
| 11 | Section 07, pay ratio | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “CEO Pay Ratio”. As printed: 23 : 1. Filing ↗machine: span 1069852–1069856 |
| 12 | Section 08, Roy D. Baynes | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 668,786. Filing ↗machine: t70 · r3 · c9 · span 243391–243398 |
| 13 | Section 08, Roger Dansey | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 421,684. Filing ↗machine: t70 · r4 · c9 · span 245435–245442 |
| 14 | Section 08, Julia P. Gregory | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 258,968. Filing ↗machine: t70 · r2 · c9 · span 241584–241591 |
| 15 | Section 08, Paul M. Silva | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 230,322. Filing ↗machine: t70 · r10 · c9 · span 256805–256812 |
| 16 | Section 08, Judith A. Reinsdorf | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 229,072. Filing ↗machine: t70 · r8 · c9 · span 253088–253095 |
| 17 | Section 08, David L. Lacey | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 226,571. Filing ↗machine: t70 · r7 · c9 · span 251037–251044 |
| 18 | Section 08, Edward C. Saltzman | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 220,218. Filing ↗machine: t70 · r9 · c9 · span 254862–254869 |
| 19 | Section 08, Anil Kapur | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 217,926. Filing ↗machine: t70 · r5 · c9 · span 247201–247208 |
| 20 | Section 08, Lori A. Kunkel | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 208,447. Filing ↗machine: t70 · r6 · c9 · span 249261–249268 |
| 21 | Section 08, Arthur T. Sands | DEF 14A | 2026-03-27 | 0001140361-26-011492 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 02, Christine Ring 2026-04-02 | Form 4 | 2026-04-02 | 0001817199-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Hans van Houte 2026-04-30 | Form 4 | 2026-04-30 | 0001817217-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Hans van Houte 2026-04-30 | Form 4 | 2026-04-30 | 0001817217-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Hans van Houte 2026-04-30 | Form 4 | 2026-04-30 | 0001817217-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Christine Ring 2026-04-30 | Form 4 | 2026-04-30 | 0001817199-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Hans van Houte 2026-04-30 | Form 4 | 2026-04-30 | 0001817217-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Christine Ring 2026-04-30 | Form 4 | 2026-04-30 | 0001817199-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Christine Ring 2026-04-30 | Form 4 | 2026-04-30 | 0001817199-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Gwenn Hansen 2026-04-30 | Form 4 | 2026-04-30 | 0001817160-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Gwenn Hansen 2026-04-30 | Form 4 | 2026-04-30 | 0001817160-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Christine Ring 2026-04-30 | Form 4 | 2026-04-30 | 0001817199-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Gwenn Hansen 2026-04-30 | Form 4 | 2026-04-30 | 0001817160-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Hans van Houte 2026-04-30 | Form 4 | 2026-04-30 | 0001817217-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Christine Ring 2026-04-30 | Form 4 | 2026-04-30 | 0001817199-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Hans van Houte 2026-04-30 | Form 4 | 2026-04-30 | 0001817217-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Gwenn Hansen 2026-04-30 | Form 4 | 2026-04-30 | 0001817160-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Christine Ring 2026-04-30 | Form 4 | 2026-04-30 | 0001817199-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Gwenn Hansen 2026-04-30 | Form 4 | 2026-04-30 | 0001817160-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Gwenn Hansen 2026-04-30 | Form 4 | 2026-04-30 | 0001817160-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Gwenn Hansen 2026-04-30 | Form 4 | 2026-04-30 | 0001817160-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Christine Ring 2026-04-30 | Form 4 | 2026-04-30 | 0001817199-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Hans van Houte 2026-04-30 | Form 4 | 2026-04-30 | 0001817217-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Christine Ring 2026-05-01 | Form 4 | 2026-05-01 | 0001817199-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Christine Ring 2026-05-04 | Form 4 | 2026-05-04 | 0001817199-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Hans van Houte 2026-05-05 | Form 4 | 2026-05-05 | 0001817217-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Hans van Houte 2026-05-05 | Form 4 | 2026-05-05 | 0001817217-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Julia P. Gregory 2026-05-15 | Form 4 | 2026-05-15 | 0001226675-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Roy D. Baynes 2026-05-15 | Form 4 | 2026-05-15 | 0001680739-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Paul M. Silva 2026-05-15 | Form 4 | 2026-05-15 | 0001446372-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Edward C. Saltzman 2026-05-15 | Form 4 | 2026-05-15 | 0001946233-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Anil Kapur 2026-05-15 | Form 4 | 2026-05-15 | 0001730703-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Judith A. Reinsdorf 2026-05-15 | Form 4 | 2026-05-15 | 0001305361-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, David L. Lacey 2026-05-15 | Form 4 | 2026-05-15 | 0001734422-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Roger Dansey 2026-05-15 | Form 4 | 2026-05-15 | 0001741836-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Christine Ring 2026-06-02 | Form 4 | 2026-06-02 | 0001817199-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Christine Ring 2026-06-02 | Form 4 | 2026-06-02 | 0001817199-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Christine Ring 2026-06-02 | Form 4 | 2026-06-02 | 0001817199-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Gwenn Hansen 2026-06-25 | Form 4 | 2026-06-25 | 0001817160-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Christine Ring 2026-06-25 | Form 4 | 2026-06-25 | 0001817199-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Christine Ring 2026-06-25 | Form 4 | 2026-06-25 | 0001817199-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Christine Ring 2026-06-25 | Form 4 | 2026-06-25 | 0001817199-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Christine Ring 2026-06-25 | Form 4 | 2026-06-25 | 0001817199-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Christine Ring 2026-06-25 | Form 4 | 2026-06-25 | 0001817199-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Christine Ring 2026-07-02 | Form 4 | 2026-07-02 | 0001817199-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Christine Ring 2026-07-02 | Form 4 | 2026-07-02 | 0001817199-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Christine Ring 2026-07-02 | Form 4 | 2026-07-02 | 0001817199-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Christine Ring 2026-07-02 | Form 4 | 2026-07-02 | 0001817199-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Christine Ring 2026-07-02 | Form 4 | 2026-07-02 | 0001817199-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Hans van Houte 2026-07-30 | Form 4 | 2026-07-30 | 0001817217-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Hans van Houte 2026-07-30 | Form 4 | 2026-07-30 | 0001817217-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Hans van Houte 2026-07-30 | Form 4 | 2026-07-30 | 0001817217-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Hans van Houte 2026-07-30 | Form 4 | 2026-07-30 | 0001817217-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Christine Ring 2026-07-30 | Form 4 | 2026-07-30 | 0001817199-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Christine Ring 2026-07-30 | Form 4 | 2026-07-30 | 0001817199-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Gwenn Hansen 2026-07-30 | Form 4 | 2026-07-30 | 0001817160-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Gwenn Hansen 2026-07-30 | Form 4 | 2026-07-30 | 0001817160-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Gwenn Hansen 2026-07-30 | Form 4 | 2026-07-30 | 0001817160-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Gwenn Hansen 2026-07-30 | Form 4 | 2026-07-30 | 0001817160-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Christine Ring 2026-07-30 | Form 4 | 2026-07-30 | 0001817199-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Christine Ring 2026-07-30 | Form 4 | 2026-07-30 | 0001817199-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Christine Ring 2026-07-30 | Form 4 | 2026-07-30 | 0001817199-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Christine Ring 2026-07-30 | Form 4 | 2026-07-30 | 0001817199-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Christine Ring 2026-07-30 | Form 4 | 2026-07-30 | 0001817199-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Gwenn Hansen 2026-07-30 | Form 4 | 2026-07-30 | 0001817160-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Gwenn Hansen 2026-07-30 | Form 4 | 2026-07-30 | 0001817160-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Hans van Houte 2026-07-30 | Form 4 | 2026-07-30 | 0001817217-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Hans van Houte 2026-07-30 | Form 4 | 2026-07-30 | 0001817217-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Hans van Houte 2026-07-30 | Form 4 | 2026-07-30 | 0001817217-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Gwenn Hansen 2026-07-30 | Form 4 | 2026-07-30 | 0001817160-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 06, 2026 vote | Form 8-K | 2026-05-15 | 0001549595-26-000028 | Item 5.07 · say-on-pay result. As reported: 91.31% (votes for as printed: 72,458,920). Filing ↗ |
| 92 | Section 06, 2025 vote | Form 8-K | 2025-05-19 | 0001549595-25-000067 | Item 5.07 · say-on-pay result. As reported: 81.45% (votes for as printed: 49,788,975). Filing ↗ |
| 93 | Section 06, 2024 vote | Form 8-K | 2024-05-21 | 0001549595-24-000073 | Item 5.07 · say-on-pay result. As reported: 88.3% (votes for as printed: 30,364,001). Filing ↗ |
| 94 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 95 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 96 | Section 09b board cost (computed) | Computed | — | computed | Cash 538,231 + equity 0 + all other 1 = 538,232, summed across the director compensation table rows.machine: formula: Σ = 538,232 |
| 97 | RAPT Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-14 | 0000950170-25-053517 | CEO total compensation as printed in RAPT Therapeutics, Inc.'s own proxy. As printed: 6,979,539. Filing ↗machine: r2 · c23 · span 816852–816861 |
| 98 | Nurix Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-03-27 | 0001140361-26-011492 | CEO total compensation as printed in Nurix Therapeutics's own proxy. As printed: 6,374,138. Filing ↗machine: r2 · c21 · span 570227–570236 |
| 99 | Celldex Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050884 | CEO total compensation as printed in Celldex Therapeutics, Inc.'s own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866 |
| 100 | Mersana Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-29 | 0001104659-25-040448 | CEO total compensation as printed in Mersana Therapeutics, Inc.'s own proxy. As printed: 1,613,754. Filing ↗machine: t16 · r1 · c41 · span 608188–608197 |
| 101 | Section 10a, Mersana Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-25-040448 | Mersana Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Nurix Therapeutics. Filing ↗ |
| 102 | Section 10a, Celldex Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-050884 | Celldex Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Nurix Therapeutics. Filing ↗ |